| [1] |
Schiller GJ, Tuttle P, Desai P. Allogeneic hematopoietic stem cell transplantation in FLT3-ITD-positive acute myelogenous leukemia: the role for FLT3 tyrosine kinase inhibitors post-transplantation[J]. Biol Blood Marrow Transplant, 2016, 22(6): 982-990.
doi: 10.1016/j.bbmt.2016.01.013
URL
|
| [2] |
Yanada M, Matsuo K, Suzuki T, et al. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta-analysis[J]. Leukemia, 2005, 19(8): 1345-1349.
pmid: 15959528
|
| [3] |
Small D. FLT3 mutations: biology and treatment[J]. Hematology Am Soc Hematol Educ Program, 2006: 178-184.
|
| [4] |
Port M, Böttcher M, Thol F, et al. Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger than 60 years: a systematic review and meta-analysis[J]. Ann Hematol, 2014, 93(8): 1279-1286.
doi: 10.1007/s00277-014-2072-6
pmid: 24801015
|
| [5] |
Chang P, Kang M, Xiao A, et al. FLT3 mutation incidence and timing of origin in a population case series of pediatric leukemia[J]. BMC Cancer, 2010, 10: 513-519.
doi: 10.1186/1471-2407-10-513
URL
|
| [6] |
Whitman SP, Ruppert AS, Radmacher MD, et al. FLT3 D835/I836 mutations are associated with poor disease-free survival and a distinct gene-expression signature among younger adults with de novo cytogenetically normal acute myeloid leukemia lacking FLT3 internal tandem duplications[J]. Blood, 2008, 111(3): 1552-1559.
doi: 10.1182/blood-2007-08-107946
pmid: 17940205
|
| [7] |
Bacher U, Haferlach C, Kern W, et al. Prognostic relevance of FLT3-TKD mutations in AML: the combination matters-an analysis of 3082 patients[J]. Blood, 2008, 111(5): 2527-2537.
doi: 10.1182/blood-2007-05-091215
URL
|
| [8] |
Gallogly MM, Lazarus HM, Cooper BW. Midostaurin: a novel therapeutic agent for patients with FLT3-mutated acute myeloid leukemia and systemic mastocytosis[J]. Ther Adv Hematol, 2017, 8(9): 245-261.
doi: 10.1177/2040620717721459
pmid: 29051803
|
| [9] |
Rossi G, Minervini MM, Carella AM, et al. Wilms’tumor gene(WT1) expression and minimal residual disease in acute myeloid leukemia//van den Heuvel-Eibrink MM. Wilms tumor[M]. Brisbane(AU): Codon Publications, 2016: 273-280.
|
| [10] |
Gray JX, McMillen L, Mollee P, et al. WT1 expression as a marker of minimal residual disease predicts outcome in acute myeloid leukemia when measured post-consolidation[J]. Leuk Res, 2012, 36(4): 453-458.
doi: 10.1016/j.leukres.2011.09.005
URL
|
| [11] |
Polák J, Hájková H, Maalaufová-Soukupová J, et al. Estimation of molecular upper remission limit for monitoring minimal residual disease in peripheral blood of acute myeloid leukemia patients by WT1 expression[J]. Exp Ther Med, 2012, 3(1): 129-133
doi: 10.3892/etm.2011.363
URL
|
| [12] |
Lyu X, Xin Y, Mi R, et al. Overexpression of Wilms tumor 1 gene as a negative prognostic indicator in acute myeloid leukemia[J]. PLoS One, 2014, 9(3): e92470.
doi: 10.1371/journal.pone.0092470
URL
|
| [13] |
Cilloni D, Renneville A, Hermitte F, et al. Real-time quantitative polymerase chain reaction detection of minimal residual disease by standardized WT1 assay to enhance risk stratification in acute myeloid leukemia[J]. J Clin Oncol, 2009, 27(31): 5195-5201.
doi: 10.1200/JCO.2009.22.4865
URL
|
| [14] |
Roskoski R Jr. Properties of FDA-approved small molecule phosphatidylinositol 3-kinase inhibitors prescribed for the treatment of malignancies[J]. Pharmacol Res, 2016, 113(85): 395-408.
doi: 10.1016/j.phrs.2016.09.011
URL
|
| [15] |
Zidan MA, Kamal Shaaban HM, Elghannam DM. et al. Prognostic impact of Wilms tumor gene mutations in Egyptian patients with acute myeloid leukemia with normal karyotype[J]. Hematology, 2014, 19(5):267-274.
doi: 10.1179/1607845413Y.0000000129
URL
|
